- Home
- AU vs RGEN Comparison
AU vs RGEN Comparison
Compare AU & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- RGEN
- Stock Information
- Founded
- AU 1944
- RGEN 1981
- Country
- AU United States
- RGEN United States
- Employees
- AU N/A
- RGEN N/A
- Industry
- AU Precious Metals
- RGEN Medical/Dental Instruments
- Sector
- AU Basic Materials
- RGEN Health Care
- Exchange
- AU Nasdaq
- RGEN Nasdaq
- Market Cap
- AU 9.6B
- RGEN 8.2B
- IPO Year
- AU 1972
- RGEN N/A
- Fundamental
- Price
- AU $28.29
- RGEN $141.78
- Analyst Decision
- AU Hold
- RGEN Buy
- Analyst Count
- AU 5
- RGEN 10
- Target Price
- AU $28.50
- RGEN $188.38
- AVG Volume (30 Days)
- AU 1.6M
- RGEN 926.2K
- Earning Date
- AU 08-06-2024
- RGEN 10-29-2024
- Dividend Yield
- AU 0.78%
- RGEN N/A
- EPS Growth
- AU N/A
- RGEN N/A
- EPS
- AU 0.27
- RGEN N/A
- Revenue
- AU $4,948,000,000.00
- RGEN $602,354,000.00
- Revenue This Year
- AU $27.08
- RGEN $0.08
- Revenue Next Year
- AU $4.09
- RGEN $12.97
- P/E Ratio
- AU $100.99
- RGEN N/A
- Revenue Growth
- AU 9.18
- RGEN N/A
- 52 Week Low
- AU $14.91
- RGEN $110.45
- 52 Week High
- AU $32.57
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- AU 45.67
- RGEN 43.50
- Support Level
- AU $26.43
- RGEN $138.80
- Resistance Level
- AU $29.40
- RGEN $150.72
- Average True Range (ATR)
- AU 0.66
- RGEN 4.98
- MACD
- AU -0.33
- RGEN -0.92
- Stochastic Oscillator
- AU 39.31
- RGEN 24.50
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About RGEN Repligen Corporation
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.